BioRestorative Therapies (NASDAQ:BRTX) Releases Earnings Results, Beats Estimates By $0.07 EPS

BioRestorative Therapies (NASDAQ:BRTX) released its quarterly earnings results on Thursday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.07, Zacks reports. The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.48 million. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%.

BioRestorative Therapies Stock Down 1.1 %

Shares of BioRestorative Therapies stock opened at $1.81 on Friday. The company’s 50-day simple moving average is $1.97 and its 200-day simple moving average is $1.72. The firm has a market cap of $12.53 million, a price-to-earnings ratio of -1.18 and a beta of 64.37. BioRestorative Therapies has a 52-week low of $1.03 and a 52-week high of $2.55.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.